SHR-1210

PreclinicalSmall molecule

JJiangsu HengRui Medicine Co., Ltd.

SHR-1210 is one of 24 small molecule programs targeting Radiotherapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RadiotherapyCompleted

RadiotherapyPreclinical

Completed

Competition

Competitive Landscape

26 competitors in Radiotherapy

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Erbitux

IImclone

Phase 3

5 3

Bavencio

EMD Serono

Phase 3

3 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 5

Imfinzi

AstraZeneca

Phase 2

5 6

Tecentriq

Roche

Phase 2

3 7

Eloxatin

Teva

Phase 2

2 8

Imjudo

AstraZeneca

Phase 2

2 9

Avastin

Roche

Phase 2

2 10

Abraxane

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT04014101·40 enrolled

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT03722875·45 enrolled

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 1/2·NCT02942329·60 enrolled

Lymphoma3 trials

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03155425·75 enrolled

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03363555·97 enrolled

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT03250962·280 enrolled

Non-Small Cell Lung Cancer3 trials

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03083041·210 enrolled

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03777124·25 enrolled

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT04506242·74 enrolled

Gastric Cancer2 trials

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03472365·67 enrolled

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03813784·885 enrolled

PD-1 Inhibitor2 trials

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03605706·396 enrolled

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT03557411·42 enrolled

31 more indications

Non-squamous NSCLC2 trials

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03666728·5 enrolled

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03134872·419 enrolled

Treatment2 trials

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03417895·59 enrolled

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 1/2·NCT04133337·20 enrolled

Chemotherapy2 trials

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03092895·157 enrolled

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03671265·20 enrolled

Esophageal Cancer2 trials

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Completed·HHangzhou Cancer Hospital·Phase 2·NCT03187314·25 enrolled

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03691090·596 enrolled

Advanced2 trials

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

Unknown status·HHarbin Medical University·Phase 1/2·NCT03601598·41 enrolled

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT02989922·220 enrolled

Cervical Cancer2 trials

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04680988·194 enrolled

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Completed·SSun Yat-sen University·Phase 2·NCT03816553·45 enrolled

Nasopharyngeal Carcinoma1 trial

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03558191·156 enrolled

Metastatic Colorectal Cancer1 trial

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03645876·12 enrolled

Total Neoadjuvant Treatment1 trial

Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT04340401·25 enrolled

Advanced Refractory Solid Tumors1 trial

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT03171220·40 enrolled

Advanced Solid Tumor1 trial

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02721589·126 enrolled

Recurrent or Metastatic1 trial

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC

Unknown status·SSun Yat-sen University·Phase 1·NCT03527251·10 enrolled

Esophageal Squamous Cell Cancer1 trial

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03603756·45 enrolled

Safety and Efficacy1 trial

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03121716·23 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT04533490·42 enrolled

Carboplatin1 trial

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03668496·390 enrolled

First Line Therapy1 trial

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03764293·543 enrolled

Concurrent Chemoradiotherapy1 trial

A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03817658·725 enrolled

Relapsed/Refractory1 trial

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Unknown status·—·Phase 1/2·NCT03346642·30 enrolled

Small Cell Lung Cancer1 trial

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04790539·71 enrolled

Melanoma1 trial

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02738489·36 enrolled

Patients With Advanced Solid Tumors1 trial

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03182673·31 enrolled

Completed·PPeking University People's Hospital·Phase 2·NCT03359018·43 enrolled

Radiotherapy1 trial

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Completed·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03222440·20 enrolled

Trial1 trial

A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）

Unknown status·YYanqiao Zhang·Phase 1/2·NCT04298320·40 enrolled

Gynecological Tumors1 trial

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03827837·265 enrolled

Advanced or Metastatic NSCLC1 trial

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03085069·146 enrolled

Resectable NSCLC1 trial

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Unknown status·XXuanwu Hospital, Beijing·Phase 2·NCT04108013·38 enrolled

Unspecified1 trial

A SHR-1210 BE Study on Healthy Subjects

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05799183·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 50 trial records for SHR-1210. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-1210 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-1210. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

SHR-1210

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Lymphoma3 trials

Non-Small Cell Lung Cancer3 trials

Gastric Cancer2 trials

PD-1 Inhibitor2 trials

Non-squamous NSCLC2 trials

Treatment2 trials

Chemotherapy2 trials

Esophageal Cancer2 trials

Advanced2 trials

Cervical Cancer2 trials

Nasopharyngeal Carcinoma1 trial

Metastatic Colorectal Cancer1 trial

Total Neoadjuvant Treatment1 trial

Advanced Refractory Solid Tumors1 trial

Advanced Solid Tumor1 trial

Recurrent or Metastatic1 trial

Esophageal Squamous Cell Cancer1 trial

Safety and Efficacy1 trial

Esophageal Squamous Cell Carcinoma1 trial

Carboplatin1 trial

First Line Therapy1 trial

Concurrent Chemoradiotherapy1 trial

Relapsed/Refractory1 trial

Small Cell Lung Cancer1 trial

Melanoma1 trial

Patients With Advanced Solid Tumors1 trial

Renal Cell Carcinoma1 trial

Anti-PD-1 Antibody1 trial

Osteosarcoma1 trial

Radiotherapy1 trial

Trial1 trial

Gynecological Tumors1 trial

Advanced or Metastatic NSCLC1 trial

Resectable NSCLC1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News